Revenue
No reported data
MiNK Therapeutics, Inc. (INKT)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $5.8M | $6.3M | $15.5M | $23.1M | $14.0M | $9.5M |
| Operating income | −$12.6M | −$11.3M | −$22.9M | −$30.9M | −$28.4M | −$14.6M |
| Net income | −$12.5M | −$10.8M | −$22.5M | −$28.0M | −$30.2M | −$16.2M |
| Basic EPSper diluted share | -$2.93 | -$2.86 | -$6.54 | -$0.83 | -$1.16 | -$0.67 |
| Diluted EPSper diluted share | -$2.93 | -$2.86 | -$6.54 | -$0.83 | -$1.16 | -$0.67 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 4, 2026Form 4 | Ryan BarbaraDirector | SellCommon Stock | 1.0K | $12.80 | $12.8K | 22.0K |
| Jun 4, 2026Form 4 | Ryan BarbaraDirector | SellCommon Stock | 500 | $12.68 | $6.3K | 23.0K |
| Mar 10, 2026Form 4 | Ryan BarbaraDirector | SellCommon Stock | 500 | $15.30 | $7.7K | 20.4K |
| Mar 10, 2026Form 4 | Ryan BarbaraDirector | SellCommon Stock | 500 | $15.57 | $7.8K | 20.9K |
| Mar 10, 2026Form 4 | Ryan BarbaraDirector | SellCommon Stock | 300 | $15.28 | $4.6K | 21.4K |